CalciMedica Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CALCIMEDICA, INC. | ||
| Date: March 28, 2024 | By: | /s/ A. Rachel Leheny |
|---|---|---|
| A. Rachel Leheny, Ph.D. | ||
| Chief Executive Officer(Principal Executive Officer) | ||
| Date: March 28, 2024 | By: | /s/ Daniel Geffken |
| Daniel Geffken | ||
| Interim Chief Financial Officer(Principal Accounting and Financial Officer) | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints A. Rachel Leheny, Ph.D. and Daniel Geffken, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ A. Rachel Leheny | Chief Executive Officer and Director | March 28, 2024 |
| A. Rachel Leheny, Ph.D. | (Principle Executive Officer) | |
| /s/ Daniel Geffken | Interim Chief Financial Officer | March 28, 2024 |
| Daniel Geffken | (Principal Accounting and Financial Officer) | |
| /s/ Robert N. Wilson | Chairman | March 28, 2024 |
| Robert N. Wilson | ||
| /s/ Eric Bjerkholt | Director | March 28, 2024 |
| Eric Bjerkholt | ||
| /s/ Frederic Guerard, Pharm.D. | Director | March 28, 2024 |
| Frederic Guerard, Pharm.D. | ||
| /s/ Fred Middleton | Director | March 28, 2024 |
| Fred Middleton | ||
| /s/ Eric W. Roberts | Director | March 28, 2024 |
| Eric W. Roberts | ||
| /s/ Allan Shaw | Director | March 28, 2024 |
| Allan Shaw | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm PCAOB ID: 42 | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-3 |
| Consolidated Statements of Operations for the Years ended December 31, 2023 and 2022 | F-4 |
| Consolidated Statements of Comprehensive Loss for Years ended December 31, 2023 and 2022 | F-5 |
| Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the Years ended December 31, 2023 and 2022 | F-6 |
| Consolidated Statements of Cash Flows for the Years ended December 31, 2023 and 2022 | F-8 |
| Notes to Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.